fda approval of tirzepatide for Weight Loss Receives Lilly's Zepbound (aka tirzepatide) Lands

L.et al (2011)

BPC-157 is derived from gastric juice proteins and studied for tissue healing

Fat dissolving targets areas like love handles, belly fat, or a double chin with a customised approach

The introduction of GLP-1 receptor agonists and subsequent multi-agoniststargeting pathways like GIP, amylin, and glucagonhas revolutionized clinical outcomes

By Yuki Noguchi, Carmel Wroth Updated March 22, 2024 at 12:18 PM ET For the first time, Medicare will allow coverage of one of the new blockbuster weight-loss drugs for enrollees in Part D plans

Zepbound and Mounjaro have even more impressive results: They can help people lose up to 21 percent of their total body weight